AI Article Synopsis
- * A significant portion of TSC patients, at least one-third, experience drug-resistant epilepsy (DRE), presenting a major challenge for treatment.
- * A case study highlights a patient with multifocal DRE from TSC who was successfully treated with deep brain stimulation of the anterior thalamic nucleus, showing positive results after eight months.
Article Abstract
Tuberous sclerosis complex (TSC) is an autosomal dominant disorder caused by mutations in the tumor suppressor genes TSC1 or TSC2. TSC is characterized by the formation of multiple tumors in various organs. The most common neurological manifestation of the disorder is epilepsy present in 79-90% of cases. At least one-third of TSC patients develop drug-resistant epilepsy (DRE) which remains a great challenge for clinicians. Neuromodulation is an option in cases of multifocal epilepsy, epilepsy originating in eloquent areas, or the inability to identify the ictal onset zone. Deep brain stimulation of the anterior thalamic nucleus (ANT-DBS) may be used in the treatment of multifocal DRE. Here, we present a case of a patient with multifocal DRE caused by TSC, who was treated with ANT-DBS. A follow-up period of eight months showed that the patient's multifocal DRE was successfully treated by ANT-DBS.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10750026 | PMC |
| http://dx.doi.org/10.1016/j.ebr.2023.100637 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Responsive Neurostimulation in Pediatric and Young Adult Patients With Drug-Resistant Focal, Multifocal, and Generalized Epilepsy: A Single-Center Experience.
Pediatr Neurol
December 2024
Division of Pediatric Neurology, Department of Pediatrics, University of Utah School of Medicine, Salt Lake City, Utah; Department of Pediatrics, Intermountain Healthcare, Salt Lake City, Utah.
Background: Responsive neurostimulation (RNS) is used off-label in pediatric patients with drug-resistant epilepsy (DRE). Our study aims to assess the safety and efficacy of RNS in pediatric and young adult patients with focal, multifocal, and generalized DRE.
Methods: All patients who underwent RNS implantation at Primary Children's Hospital in Salt Lake City, UT, between December 2017 and 2022.
Bilateral pulvinar responsive neurostimulation for bilateral multifocal posteriorly dominant drug resistant epilepsy.
Epilepsia Open
December 2024
Department of Neuroscience, Corewell Health, Grand Rapids, Michigan, USA.
Article Synopsis
- The study describes four cases of Responsive Neurostimulation (RNS) targeting the bilateral pulvinar nuclei in patients with drug-resistant epilepsy, highlighting that this method could benefit those with bilateral multifocal epilepsy due to the PUL's extensive connectivity.
- Conducted at two medical centers, the research involved patients implanted with bilateral PUL RNS between 2019 and 2022, detailing target selection, device programming, and clinical outcomes.
- The results showed significant reductions in disabling seizures for all patients, with no adverse effects reported, indicating that RNS targeting the PUL might be a safe and effective treatment option for specific epilepsy cases.
Factors associated with poor sleep in children with drug-resistant epilepsy.
Epilepsia
November 2024
Paediatric Neurology Department, University Hospitals Leuven, KU Leuven, Leuven, Belgium.
Article Synopsis
- The study wanted to learn about how sleep is affected in kids with a tough type of epilepsy called drug-resistant epilepsy (DRE).
- They compared the sleep quality of kids with well-controlled epilepsy (WCE) to those with DRE, finding that DRE kids had worse sleep.
- Factors like certain brain waves and medications were linked to poorer sleep, and the researchers hope this information can help improve sleep and health for these children.
Responsive neurostimulation in pediatric epilepsy: a systematic review and individual patient meta-analysis supplemented by a single institution case series in 105 aggregated patients.
Childs Nerv Syst
November 2024
School of Medicine, New York Medical College, Valhalla, NY, USA.
Purpose: To assess responsive neurostimulation (RNS) efficacy in pediatric patients with drug-resistant epilepsy, comparing response (≥ 50% reduction in seizure frequency) rates between patients with two or fewer seizure foci and those with multifocal or generalized epilepsy. This study seeks to address the gap in knowledge regarding RNS effectiveness in pediatric populations.
Methods: A systematic review and meta-analysis included data from PubMed, Embase, and Web of Science through November 2023, including 17 retrospective studies and a case series of 24 patients from our practice for a total of 105 aggregated patients.
Centromedian region thalamic responsive neurostimulation mitigates idiopathic generalized and multifocal epilepsy with focal to bilateral tonic-clonic seizures.
Epilepsia
September 2024
Department of Neurosurgery, Massachusetts General Hospital, Boston, Massachusetts, USA.
Objective: Although >30% of epilepsy patients have drug-resistant epilepsy (DRE), typically those with generalized or multifocal disease have not traditionally been considered surgical candidates. Responsive neurostimulation (RNS) of the centromedian (CM) region of the thalamus now appears to be a promising therapeutic option for this patient population. We present outcomes following CM RNS for 13 patients with idiopathic generalized epilepsy (IGE) and eight with multifocal onsets that rapidly generalize to bilateral tonic-clonic (focal to bilateral tonic-clonic [FBTC]) seizures.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!